AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Early-Onset Myopia Intervention Project

RecruitingNAAges 3 Years - 6 YearsAllShanghai Eye Disease Prevention and Treatment Cenโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The prevalence of myopia among children has been increasing year by year, which has become a globle public health issue. Studies have shown that defocusing lenses and atroping eyedrops can control the progression of myopia, but there is little evidence of its efficacy in myopia intervention of young pre-schoolers who will face a greater risk of progression to high myopia later in life. Therefore, this study aims to evaluate the effectiveness and safety of spectacle lenses with highly aspherical lenslets (Essilor's Stellest) , as well as 0.01% and 0.05% low concentration atropine eyedrops in myopia intervention among young children aged 3-6.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age 3-6 years, gender unrestricted; * Bilateral cycloplegic spherical equivalent (SE) โ‰ค +0.75 D, astigmatism โ‰ค-2.5 D, anisometropia โ‰ค2.5 D; * Best corrected visual acuity: โ‰ฅ0.5 for ages 3-5, โ‰ฅ0.7 for age 6; * Accept regular follow-up, written informed consent from guardians, verbal informed consent from children; * Possess normal thinking and language communication skills, and can actively cooperate to wear spectacles as required. Exclusion Criteria: * Existence of strabismus or amblyopia or other binocular vision abnormalities, accommodation dysfunction, cataract and history of eye surgery; * Any ocular or systemic disease that may affect vision and refractive development (e.g., Keratoconus, Marfan syndrome, retinopathy of prematurity, etc.); * Current or previous use of other treatments for myopia intervention, such as pharmacological (atropine) and optical (orthokeratology lenses or DIMS spectacle lenses) approaches, interrupt use for at least 4 weeks; * Allergy or contraindication to cycloplegic drugs; * Epilepsy or other mental disorders unable to expressing consent; * Other conditions deemed unsuitable for participation by the researcher.
๐Ÿ’Š

What it tests

  • 0.01% atropine eye drops
  • 0.05% atropine eye drops
  • Spectacle lenses with highly aspherical lenslets
๐Ÿ“

Where

1 site
Shanghai Eye Disease Prevention and Treatment Center
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy